Markets:

Overview

News

Currencies

International

Treasuries

Johnson & Johnson (NY:JNJ)

195.93 +0.68 (+0.35%)

Official Closing Price Updated: 7:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

99 100 Next >

10 Health Care Stocks Whale Activity In Today's Session ↗

December 05, 2024

Via Benzinga

Celebrating innovation happens from the inside out

December 04, 2024

(BPT) - For more than a century, Johnson & Johnson has been synonymous with innovation in science and medicine by moving the needle in building a world where complex diseases are prevented and cured,...

Via Brandpoint

Ray Dalio's Bridgewater Adds Broadcom, Apple, SMCI In Q3, While Offloading Stake In AI Giant Nvidia And Other Big Tech Companies ↗

December 03, 2024

Bridgewater Associates, the world's biggest hedge fund, sold top AI-linked stocks like Nvidia, Alphabet, Microsoft, Amazon, and Johnson & Johnson.

Via Benzinga

Topics Artificial Intelligence

3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later ↗

December 01, 2024

Via The Motley Fool

Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity ↗

November 21, 2024

Via Benzinga

Price Over Earnings Overview: Johnson & Johnson ↗

November 21, 2024

Via Benzinga

This Is What Whales Are Betting On Johnson & Johnson ↗

November 15, 2024

Via Benzinga

Bristol-Myers Squibb Files Lawsuit Against US Agency For Overreach In 340B Drug Pricing Program ↗

November 29, 2024

Bristol Myers Squibb sues HRSA, claiming its rejection of a rebate model for 340B pricing violates federal law. The lawsuit highlights concerns over program abuse and regulatory overreach.

Via Benzinga

Topics Lawsuit

2 Very Healthy Dividend Stocks to Hold for Decades of Income ↗

November 26, 2024

Via The Motley Fool

3 Dividend Stocks That Are Screaming Buys in November ↗

November 23, 2024

Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends.

Via The Motley Fool

2 Unstoppable Dividend Stocks to Buy Now With $500 ↗

November 23, 2024

Via The Motley Fool

2 Dow Jones Dividend Stocks With Yields Above 3% You Can Buy Now and Hold at Least a Decade ↗

November 23, 2024

Via The Motley Fool

Topics Stocks

ORIC: Working with Two Pharma Giants, Analysts See +100% Upside

November 16, 2024

ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this firm is all about.

Via MarketBeat

Industry Comparison: Evaluating Johnson & Johnson Against Competitors In Pharmaceuticals Industry ↗

November 07, 2024

Via Benzinga

Comparative Study: Johnson & Johnson And Industry Competitors In Pharmaceuticals Industry ↗

October 24, 2024

Via Benzinga

This Johnson & Johnson Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

November 15, 2024

Via Benzinga

Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower ↗

November 14, 2024

Trump may appoint Robert F. Kennedy Jr. as HHS Secretary, stirring mixed reactions. Kennedy's views on vaccines could reshape policies and affect vaccine stocks.

Via Benzinga

Topics Government

Cidara Therapeutics' Unique Cloudbreak Platform And Its Promise In Influenza And Oncology ↗

November 14, 2024

CDTX sold its Rezayo business to concentrate on its MDC-producing Cloudbreak platform which has already produced several promising drug candidates, like CD388, a very promising clinical-stage...

Via Talk Markets

Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day? ↗

November 14, 2024

Stocks in these "safe" sectors are selling off as investors gravitate toward growth.

Via The Motley Fool

Topics ETFs Stocks

Johnson & Johnson Challenges Government Drug Pricing Dispute Over Two Drugs ↗

November 13, 2024

Johnson & Johnson sues the U.S. government agency over a 340B Drug Pricing Program dispute, arguing the program's misuse.

Via Benzinga

Topics Lawsuit

Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever ↗

November 08, 2024

You'll also like these stocks for their track record of earnings growth.

Via The Motley Fool

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields ↗

November 06, 2024

Via Benzinga

Discover the 3 Best-Performing Biotech IPO Stocks of 2024

November 06, 2024

Check out which three biotechnology companies that went public in 2024 and are performing the best and a big factor influenced their rise.

Via MarketBeat

Topics Initial Public Offering

Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare

November 04, 2024

Inovalon Unveils New Research, Products, and Solutions to Tackle Healthcare’s Most Complex Challenges

From Inovalon Holdings, Inc.

Via GlobeNewswire

Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises ↗

October 28, 2024

Global psychedelic drugs market to reach $10.2 billion by 2028, driven by mental health needs and evolving regulatory support.

Via Benzinga

Johnson & Johnson's Tremfya Seeks Expanded Use Approval After It Shares Encouraging Late-Stage Study Data In Crohn's Disease ↗

October 28, 2024

Johnson & Johnson's Tremfya shows promising results in Phase 3 GRAVITI study for Crohn's disease, achieving significant clinical remission and endoscopic response at 48 weeks.

Via Benzinga

3 Dividend Growth Stocks You Can Buy and Hold Forever ↗

October 26, 2024

These healthcare stocks have fantastic dividend track records.

Via The Motley Fool

Johnson & Johnson's Blockbuster Drug Tremfya Clears Plaque Psoriasis With Lesions Covering Body's Smaller Areas ↗

October 25, 2024

Johnson & Johnson's Tremfya showed significant skin clearance in adults with low BSA moderate plaque psoriasis in the SPECTREM Phase 3b study, surpassing placebo.

Via Benzinga

Meet the Only 2 Game-Changing Businesses With a Higher Credit Rating Than the U.S. Government ↗

October 24, 2024

In 1980, around five dozen publicly traded companies held the highest possible credit rating (AAA) from Standard & Poor's. Today, there are only two left.

Via The Motley Fool

3 Simple Vanguard ETFs to Buy With $1,000 and Hold for a Lifetime ↗

October 23, 2024

These three Vanguard ETFs are worth considering for the long term.

Via The Motley Fool

Topics ETFs

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.